CoChat

Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Therapy with the oral antidiabetic agent troglitazone (Rezulin) has been associated with cases of severe hepatotoxicity and drug-induced liver failure, which led to the recent withdrawal of the product from the U.S. market. While the mechanism of this toxicity remains unknown, it is possible that chemically reactive metabolites of the drug play a causative role. In an effort to address this possibility, this study was undertaken to determine whether troglitazone undergoes metabolism in human liver microsomal preparations to electrophilic intermediates. Following incubation of troglitazone with human liver microsomes and with cDNA-expressed cytochrome P450 isoforms in the presence of glutathione (GSH), a total of five GSH conjugates (M1-M5) were detected and identified tentatively by LC-MS/MS analysis. In two cases (M1 and M5), the structures of the adducts were confirmed by NMR spectroscopy and/or by comparison with an authentic standard prepared by synthesis. The formation of GSH conjugates M1-M5 revealed the operation of two distinct metabolic activation pathways for troglitazone, one of which involves oxidation of the substituted chromane ring system to a reactive o-quinone methide derivative, while the second involves a novel oxidative cleavage of the thiazolidinedione (TZD) ring, potentially generating highly electrophilic alpha-ketoisocyanate and sulfenic acid intermediates. When troglitazone was administered orally to a rat, samples of bile were found to contain GSH conjugates which reflected the operation of these same metabolic pathways in vivo. The finding that metabolism of the TZD ring of troglitazone was catalyzed selectively by P450 3A enzymes is significant in light of the recent report that troglitazone is an inducer of this isoform in human hepatocytes. The implications of these results are discussed in the context of the potential for troglitazone to covalently modify hepatic proteins and to cause oxidative stress through redox cycling processes, either of which may play a role in drug-induced liver injury.

Overview

Integrity signals

Registry

Crossref · 10.1021/tx000180q

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 8 references

Research works printed but not linked: 16

  1. Henry R. R., 1997, Thiazolidinones. Curr. Ther. Diabetes 26, 553−573
  2. Hu J., 1999, J. Org. Chem., 64
  3. Hart T. W., 1985, Tetrahedron Lett., 26
  4. Baillie T. A., 1993, Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22, 319−325
  5. Kassahun K., 1997, Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: Identification of Phase I metabolites and glutathione conjugates. Chem. Res. Toxicol. 10, 1228−1233
  6. Borel A. G., 1993, Identification of carbomoylated thiol conjugates as metabolites of the antineoplastic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, in rats and humans. Drug Metab. Dispos. 21, 889−901
  7. Kawai K., 1997, Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneim.-Forsch. 47, 356−368
  8. Loi C. M., 1997, J. Clin. Pharmacol., 37
  9. Ohe T., 1997, Substituent elimination from p-substituted phenols by cytochrome P450. ipso-Substitution by the oxygen atom of the active species. Drug Metab. Dispos. 25, 116−122
  10. Ohe T., 2000, Novel metabolic pathway of estrone and 17β-estradiol catalyzed by cytochrome P-450. Drug Metab. Dispos. 28, 110−112
  11. Yamazaki H., 1999, Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab. Dispos. 27, 1260−1266
  12. He K., 1999, Proceedings of the 9th North American ISSX Meeting, #207
  13. Polsker G. L., 1999, Troglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 57, 409−438
  14. Ramachandran V., 1999, Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos. 27, 1194−1199
  15. Mansuy D., 1991, J. Am. Chem. Soc., 113
  16. Abbreviations TZD, thiazolidinedione

Cited by

Items 201–300 of 316

Metadata

Authors
Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., & Baillie, T. A.
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Kassahun, Kelem
Venue
Chemical Research in Toxicology
Published
2000-12-08
Volume
14
Issue
1
Pages
62-70
ISSN
  • 0893-228X (ISSN-L)
  • 1520-5010
OpenAlex
W2068532562
Cited by
311
References
8
Citations by year
2026: 2 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 9 · 2021: 10 · 2020: 5 · 2019: 4 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 9 · 2014: 15 · 2013: 12 · 2012: 16
FWCI
9.82
Type
journal article
Language
en
Open access
closed
Locations
  • Chemical Research in Toxicology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Keywords
troglitazone, drug metabolism, reactive metabolites, glutathione conjugates, CYP3A, hepatotoxicity, drug-induced liver injury, sulfenic acid, oxidative stress, redox cycling, covalent protein modification, human liver microsomes, bile
MeSH terms
Troglitazone, Animals, Bile, Biotransformation, Catalysis, Chromans, Chromatography, Liquid, Cytochrome P-450 Enzyme System, Glutathione, Humans, Hypoglycemic Agents, Isoenzymes, Ketoconazole, Kinetics, Microsomes, Liver, NADP, Mass Spectrometry, Steroid Hydroxylases, Thiazoles, Thiazolidinediones, Rats, Cytochrome P-450 Enzyme Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.